CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives
Source : https://doi.org/10.3390/cancers13020332
Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer is the most common breast cancer subtype, and endocrine therapy (ET) remains its therapeutic backbone. Although anti-estrogen therapies...
Abstract PS5-28: Multiomic advanced diagnostics for CDK 4/6 drug target activation mapping of HR+/HER2- metastatic breast cancer
Source : https://cancerres.aacrjournals.org/content/81/4_Supplement/PS5-28.short
Abstracts: 2020 San Antonio Breast Cancer Virtual Symposium; December 8-11, 2020; San Antonio, Texas Background: Three CDK 4/6 inhibitors (inh) are FDA approved in combination with endocrine therapy (ET) for...
Abstract PS7-55: Evolution of prescribing trends for HR+/HER2- metastatic breast cancer (mBC) in a post-CDK4/6i world
Source : https://cancerres.aacrjournals.org/content/81/4_Supplement/PS7-55.short
Abstracts: 2020 San Antonio Breast Cancer Virtual Symposium; December 8-11, 2020; San Antonio, Texas Background :There is limited real-world (RW) evidence describing treatment patterns among oncologists since clinical guidelines have...
CDK4/6 inhibitor plus endocrine therapy for hormone receptor‐positive, HER2‐negative metastatic breast cancer: The new standard of care
Source : https://onlinelibrary.wiley.com/doi/full/10.1111/ajco.13555
Rina Hui Corresponding Author Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, New South Wales, Australia University of Sydney, Sydney, New South Wales, Australia Correspondence Rina Hui, Crown Princess Mary...
Targeted Neoadjuvant Therapies in HR+/HER2−Breast Cancers: Challenges for Improving pCR
Source : https://www.mdpi.com/2072-6694/13/3/458
A strong association of pCR (pathological complete response) with disease-free survival or overall survival is clinically desirable. The association of pCR with disease-free survival or overall survival in ER+/HER2−breast cancers...